RNF113A and small cell lung carcinoma: Regardless of the mechanisms involved, RNF113A involvement in both cisplatin in lung adenocarcinoma and alkylation-based therapy resistance in SCLC is particularly attractive, as both agents are frequently used together in certain cancer combination treatments.